Should Thrombolytic Therapy Be Given?
Yes, thrombolytic therapy with either alteplase or tenecteplase should be administered immediately in this patient presenting at 3.5 hours with persistent, disabling left-sided weakness, even though imaging shows no acute infarction or large vessel occlusion.
Rationale Based on Current Guidelines
The 2026 AHA/ASA guidelines explicitly recommend rapid thrombolytic treatment in eligible patients with disabling deficits, regardless of NIHSS score, within the 4.5-hour window without requiring advanced imaging selection 1. Your patient is well within this window at 3.5 hours.
Key Decision Points:
Time Window: At 3.5 hours from symptom onset, this patient falls squarely within the established 4.5-hour treatment window where thrombolysis has Grade A evidence 1.
"Disabling" Weakness: The critical distinction here is whether the weakness is "disabling" versus "non-disabling." The guidelines state that for non-disabling deficits (e.g., isolated sensory syndrome), trials have failed to demonstrate benefit, and dual antiplatelet therapy is preferred 1. However, you've clarified this is persistent, significant weakness that has only slightly improved—this clearly qualifies as disabling and warrants thrombolysis.
Negative Imaging Does Not Contraindicate Treatment: The absence of visible infarction on initial CT is common in hyperacute stroke and should not delay treatment. Research specifically demonstrates that patients with acute ischemic symptoms who received IV-tPA without perfusion defects on advanced imaging still benefited significantly, with mean NIHSS reduction from 8.2 to 2.5 at discharge 2. The study concluded that "failure to identify a perfusion deficit should not be used as a contraindication for intravenous thrombolytics" 2.
No Large Vessel Occlusion: While absence of LVO means the patient is not a candidate for mechanical thrombectomy, this does not preclude thrombolysis. Many strokes involve smaller vessel occlusions or microvascular disease that respond to IV thrombolysis.
Treatment Algorithm
- Verify eligibility: Confirm no absolute contraindications (recent surgery, active bleeding, etc.)
- Administer thrombolysis immediately: Either alteplase (0.9 mg/kg, max 90 mg) or tenecteplase (weight-based single bolus) 1
- Do not delay for additional imaging: The 2026 guidelines emphasize that within 4.5 hours with disabling deficits, advanced imaging selection is not required 1
- Monitor closely: Blood pressure control, neurological checks, and surveillance for hemorrhagic transformation
Critical Pitfall to Avoid
Do not withhold thrombolysis because symptoms "slightly improved." The key phrase is that weakness "continues to be significant"—this is not a rapidly resolving deficit. Patients with truly rapidly improving symptoms to non-disabling levels are a different category, but persistent disabling weakness at 3.5 hours mandates treatment.
The extended window (4.5-24 hours) recommendations using advanced imaging 3, 4 are relevant only for patients presenting beyond 4.5 hours. Your patient at 3.5 hours should receive standard-window treatment without delay for perfusion imaging.